Cell Expansion Market Experiencing Rapid Growth 12.32% by 2032

The global cell expansion market size was evaluated at US$ 17.61 billion in 2023 and is expected to attain around US$ 56.16 billion by 2033, growing at a CAGR of 12.32% from 2024 to 2033. Ensuring product safety and maintaining cell function control are paramount in cell expansion processes for clinical applications.

Cell Expansion Market Overview

The cell expansion market is experiencing rapid growth, driven by the fundamental process of cells dividing and proliferating while maintaining functionality, known as cell expansion. This phenomenon plays a crucial role in various biological processes, such as the immune response to pathogens, which involves the proliferation of antigen-specific T cells. Notably, cell expansion is central to human inflammatory responses and certain autoimmune diseases. Key to cell expansion is the coordination of multiple cellular processes, particularly the control of ion transport during vacuolar growth, facilitating cell size increase and the production of new wall and membrane material.

Get sample copy of report@ https://www.precedenceresearch.com/sample/2795

Key Insights

• North America has captured market share of around 45.14% in 2023.
• U.S. cell expansion market size was valued at USD 5.57 billion in 2023.
• U.S. cell expansion market size is expected to reach around USD 18.67 billion by 2033 and growing at a CAGR of 12.87% from 2024 to 2033.
• By application, the biopharmaceutical segment recorded to the greatest market share of around 52% in 2023.
• By product, the consumables segment dominated the market and captured the largest market share.
• By product, the mammalian cells type segment contributed to the maximum market share.
• By end-use, the biopharmaceutical and biotechnology companies segment generated to the biggest share.

Immediate delivery is available, Get access of the full report@ https://www.precedenceresearch.com/checkout/2795

Regional Stance

North America commands the largest share of the cell expansion market, propelled by robust research efforts focusing on biologics, stem cells and genetic engineering. Leveraging stem cells as a renewable source of beta cells holds significant promise, allowing for the generation of numerous islet cells from a single pancreas. Stem cell research is integral to the biomedical research landscape in the United States, contributing to the development of life-saving therapeutics, enhancing understanding of human development and diseases, and paving the way for revolutionary cell therapies.

Canada’s Stem Cell Network (SCN) plays a pivotal role in advancing stem cell research and regenerative medicine, driving scientific breakthroughs, fueling clinical trials, and fostering the creation of new companies.

Mexico boasts a thriving stem cell industry, formal regulations on stem cell research are yet to be implemented. Mexican doctors are already utilizing stem cells to treat chronically ill patients from around the world, including Americans, afflicted with conditions such as cerebral palsy, autism, and paralysis. Continued investment in stem cell research and access to necessary resources are imperative to translate scientific advancements into tangible benefits for patients worldwide.

• In April 2023, Bristol Myers Squibb strengthened its cell therapy capabilities by adding a New U.S. manufacturing facility for viral vector production.

Asia Pacific is poised to experience rapid growth in the stem cell industry, driven by strategic initiatives and increased efforts in stem cell research and practice. In India, stem cell programs have been initiated to promote both basic and translational research, with a focus on creating centers of excellence, establishing a virtual network of centers, and generating adequate human embryonic stem cell (hESC) lines. These initiatives are shaping the strategy for promoting stem cell research in the country, fostering a conducive environment for scientific advancement and innovation.

China has intensified its endeavors in stem cell research and clinical applications. Basic research efforts primarily target bone marrow and embryonic stem cells, while clinical applications extend to treating conditions such as acute heart failure, acute liver failure, and lower limb ischemia. This concerted focus on stem cell research and practice underscores China’s commitment to leveraging advanced biotechnologies for medical innovation and addressing pressing healthcare challenges. As Asia Pacific emerges as a key player in the global stem cell industry, continued investment in research infrastructure, regulatory frameworks, and talent development will be essential to drive sustained growth and realize the full potential of stem cell therapies in improving healthcare outcomes across the region.

Ask here for customization@ https://www.precedenceresearch.com/customization/2795

Report Highlights

By Product

In the cell expansion market, the consumables segment emerged as the frontrunner in market generation, capturing the largest share. The introduction of New Cell Culture Consumables represents a significant advancement, offering heightened levels of safety, reproducibility, and reliability in cell culture work. Addressing the pressing needs of scientists and technical personnel, these innovative products from Eppendorf stand out for their ease of use, safety features, and enhanced handling capabilities, effectively mitigating the risk of contamination. With an emphasis on product purity, security, and ergonomic design, Eppendorf’s latest offerings provide superior protection against contamination while facilitating seamless and efficient cell culture processes.

By Cell Type

The mammalian cells segment retains its stronghold in the cell expansion market, continuing to command the largest market share. Widely utilized across research, clinical, and pharmaceutical sectors, mammalian cell culture serves as a pivotal tool for various applications. Derived from animal tissues, these cells are expanded in culture to facilitate the study of cell biology, disease mechanisms, and the production of essential biologics such as antibodies, proteins, and vaccines. Immortalized mammalian cell lines, capable of sustained growth in vitro, serve as invaluable models for understanding complex biological processes. However, maintaining the health and propagation of mammalian cell cultures necessitates regular passaging or subculturing.

This process involves diluting confluent cells and replenishing depleted culture media to ensure optimal growth conditions. Adhering to stringent protocols, passaging of adherent mammalian cell cultures involves enzymatic or mechanical methods to dissociate cells from culture surfaces prior to transfer to new vessels. Enzymatic methods, such as trypsinization, or mechanical techniques, like scraping, are employed to facilitate cell detachment and reattachment, ensuring the continuity of cell growth and experimentation. As the dominance of mammalian cells persists, their versatile applications and the ongoing development of advanced culture techniques are anticipated to further solidify their position in the cell expansion market.

By Application

The biopharmaceutical segment maintained its position as the frontrunner in market in 2023, boasting the greatest share. At the heart of the biotechnology and pharmaceutical industries, the development of biological drug products derived from engineered mammalian cell lines remains a central pillar. Marketed biopharmaceuticals are poised to be augmented by a plethora of clinical candidates currently in development, promising to usher in a new era of enhanced treatments for patients. Compared to traditional small molecule drugs, biotherapeutics exhibit remarkable specificity, resulting in fewer off-target interactions and improved safety profiles.

This inherent specificity not only enhances therapeutic efficacy but also minimizes adverse effects, thereby elevating the overall standard of patient care. With ongoing advancements in biopharmaceutical research and development, coupled with the proliferation of innovative clinical candidates, the landscape of the biopharmaceutical segment continues to evolve rapidly. As these promising therapies transition from development to commercialization, they are poised to address unmet medical needs and revolutionize patient treatment paradigms across various therapeutic areas.

By End-Use

The biotechnology and biopharmaceuticals companies segment emerge as the dominant force in the end-use segment, commanding the largest share. Positioned at the forefront of the biopharmaceutical and biotechnology arena, these entities play a pivotal role in advancing therapeutic technologies that utilize living cells or genetic material to address various medical conditions and illnesses. Their scope of activities encompasses a wide range of areas, including genetic disorder treatments, tissue replacement and repair therapies, cancer treatments, biosimilars, antibody therapeutics, and cell line maintenance and production technologies. Biopharmaceutical drugs, in particular, have spearheaded a revolution in disease treatment across diverse therapeutic domains, becoming integral to nearly all branches of medicine.

As these companies navigate the complex landscape of biopharmaceutical development and regulatory considerations, they are at the forefront of addressing critical issues concerning the registration of innovative biopharmaceuticals and biosimilars. Through their relentless pursuit of scientific innovation and commitment to advancing medical science, these companies are driving transformative advancements in healthcare, ushering in a new era of precision medicine and improved patient outcomes.

Market Dynamics

Driver

Advancements in Cell Expansion

Living cells are emerging as promising therapeutic entities for treating severe and chronic diseases where conventional drugs fall short. However, the potential of cell-based therapies is accompanied by numerous challenges spanning biological, regulatory, economic, logistical, safety, and engineering domains, necessitating comprehensive solutions before clinical translation. Among these challenges, cell expansion stands out as a critical operation in manufacturing cell therapy products (CTPs), significantly influencing their quantity, phenotype, and quality attributes. The demand for scalable, cost-efficient technologies and process optimization strategies in expansion processes reflects the imperative to bridge the gap between scientific research and commercially available therapies, thus propelling growth in the cell expansion market.

Restraint

Limited Proliferative Capacity

A significant challenge facing the mass production of cultured meat is the constrained proliferative capacity and slow rate of the initial cell population. This pivotal phase at the onset of the production process involves expanding a small cell sample into a robust and viable cell population. The proliferation stage’s criticality cannot be overstated, as it directly influences the efficiency and scalability of the entire downstream production process. Serving as the cornerstone of manufacturing, it dictates the success of differentiation and processing phases for the final product. These limitations restrain the growth of the cell expansion market, hindering its potential for broader adoption in cultured meat production.

Opportunity

Advancements in Automated Cell Expansion Systems

Current automated cell expansion systems are focusing on key aspects such as scalability, sterility maintenance, contamination prevention, and quality control. However, to achieve full automation in cell therapy product (CTP) manufacturing, several challenges must be addressed. These include ensuring scalability through sterile reconnections, implementing direct cell measurements for precise quality control, tackling logistical issues in traceability, maintaining temperature control during transport, and managing the administrative burden of regulations. Automation holds the promise of enhancing product quality and repeatability while reducing labor costs. Automated systems could potentially decentralize CTP manufacturing, eliminating the need for extensive cold chain logistics typically associated with CTP preservation and transportation. This shift towards automation not only streamlines processes but also creates new avenues for growth and innovation within the cell expansion market.

Recent Developments

• In May 2023, Akadeum launched T Cell activation and expansion using positive selection and expanded its Leukopak cell isolation product lines.
• In February 2024, BioCentriq presented the first public CAR-T expansion data from Terumo Blood and Cell Technologies’ Quantum Flex Cell Expansion System.
• In June 2022, Galapagos acquired CellPoint and AboundBio to accelerate access to next-generation cell therapies.
• In March 2024, Ingersoll Rand acquired ILC Dover to expand presence in life sciences.
• In November 2023, AbbVie agreed to cquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), expanding solid tumor portfolio.
• In March 2024, Roquette took a decisive strategic step and signed an agreement to Acquire IFF Pharma Solutions.

Key Players in the Cell Expansion Market

• Thermo Fisher Scientific, Inc.
• GE Healthcare
• Corning, Inc.
• STEMCELL Technologies, Inc.
• Merck KGaA
• Miltenyi Biotec
• Becton, Dickinson and Company
• Terumo Bct, Inc.
• Sartorius AG
• Takara Bio, Inc.

Market Segmentation

By Product

• Consumables
  • Reagents, Media, & Serum
  • Other Consumables
• Culture Flasks and Accessories
  • Tissue Culture Flasks
  • Other Culture Flasks and Accessories
• Instruments
  • Automated Cell Expansion Systems
  • Bioreactors
  • Other Instruments

By Cell Type

• Mammalian
  • Human
• Animal
• Others

By Application

• Biopharmaceuticals
• Tissue Culture & Engineering
• Vaccine Production
• Drug Development
• Gene Therapy
• Cancer Research
• Stem Cell Research
• Others

By End-Use

• Biopharmaceutical & Biotechnology Companies
• Research Institutes
• Cell Banks
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Immediate delivery is available, Get access of the full report@ https://www.precedenceresearch.com/checkout/2795

OR

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 | Europe: +44 2080772818

Email: sales@precedenceresearch.com